KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $1.2 billion.

  • Novavax's Liabilities and Shareholders Equity fell 3110.07% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 billion, marking a year-over-year decrease of 1963.9%. This contributed to the annual value of $1.6 billion for FY2024, which is 1318.91% down from last year.
  • Latest data reveals that Novavax reported Liabilities and Shareholders Equity of $1.2 billion as of Q3 2025, which was down 3110.07% from $1.3 billion recorded in Q2 2025.
  • Over the past 5 years, Novavax's Liabilities and Shareholders Equity peaked at $2.8 billion during Q1 2022, and registered a low of $1.2 billion during Q3 2025.
  • For the 5-year period, Novavax's Liabilities and Shareholders Equity averaged around $2.0 billion, with its median value being $1.8 billion (2023).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 69506.87% in 2021, then plummeted by 4558.14% in 2023.
  • Over the past 5 years, Novavax's Liabilities and Shareholders Equity (Quarter) stood at $2.6 billion in 2021, then fell by 12.34% to $2.3 billion in 2022, then fell by 20.42% to $1.8 billion in 2023, then decreased by 13.19% to $1.6 billion in 2024, then decreased by 24.39% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q3 2025, $1.3 billion for Q2 2025, and $1.3 billion during Q1 2025.